Ganeden BC30 supports immune health in children, says recent study

October 4, 2019

A study recent published in Food Research International found that supplementation with the branded probiotic Ganeden BC30 significantly reduced the incidence of upper respiratory tract infection (URTI) symptoms and gastrointestinal tract symptoms. In the randomized, double-blind, parallel, placebo-controlled study, 80 healthy subjects between the ages of six and eight years of age were randomized to receive either a sachet of Ganeden BC30 daily or placebo for three months.

After the three months, subjects that took the branded probiotic saw significantly less incidence of URTI symptoms, including nasal congestion, bloody nasal mucus, itchy nose, and hoarseness. Subjects taking Ganeden BC30 also had significantly less flatulence, compared to placebo. These results can be attributed to the modulation of specific immune-related proteins, significantly decreasing TNFα, CD163, G-CSF, ICAM-1, IL-6, IL-8, MCP-2, RAGE, uPAR, while increasing PF4.

“While there is already a large body of evidence for the digestive and immune health benefits of GanedenBC30, this research is particularly exciting because it is the first to focus on children, and shows the enormous potential of GanedenBC30 as a functional ingredient in products for kids,” said Don Cox, R&D director for Kerry’s proactive health division (Beloit, WI), the makers of Ganeden BC30, in a press release.